Alchemab is harnessing the power of the immune system to cure disease by using nature’s most effective search engine: adaptive immunity.
Our unique approach identifies groups of resilient individuals, such as long-term survivors of cancer, to learn how they overcome or resist disease. Using leading-edge science and deep learning, we create therapeutics from those antibodies present across the resilient population.
Our dedicated and diverse team is augmented by valued partnerships and collaborations with patient representative groups, biobanks, industry partners, and academic institutions.
Alchemab is using this approach to build a broad pipeline of protective therapeutics for hard-to-treat diseases with an initial focus on neurodegenerative conditions and oncology.